CA2172245A1 - Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein - Google Patents
Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) proteinInfo
- Publication number
- CA2172245A1 CA2172245A1 CA002172245A CA2172245A CA2172245A1 CA 2172245 A1 CA2172245 A1 CA 2172245A1 CA 002172245 A CA002172245 A CA 002172245A CA 2172245 A CA2172245 A CA 2172245A CA 2172245 A1 CA2172245 A1 CA 2172245A1
- Authority
- CA
- Canada
- Prior art keywords
- negative bacterial
- bpi
- administration
- bactericidal
- permeability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products.
Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.
Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12565193A | 1993-09-22 | 1993-09-22 | |
US08/125,651 | 1993-09-22 | ||
US27340194A | 1994-07-11 | 1994-07-11 | |
US08/273,401 | 1994-07-11 | ||
PCT/US1994/011225 WO1995008344A1 (en) | 1993-09-22 | 1994-09-22 | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2172245A1 true CA2172245A1 (en) | 1995-03-30 |
CA2172245C CA2172245C (en) | 2003-04-08 |
Family
ID=26823793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002172245A Expired - Fee Related CA2172245C (en) | 1993-09-22 | 1994-09-22 | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein |
Country Status (13)
Country | Link |
---|---|
US (2) | US5523288A (en) |
EP (1) | EP0759774B1 (en) |
JP (1) | JPH09502987A (en) |
AT (1) | ATE218880T1 (en) |
AU (1) | AU695814B2 (en) |
CA (1) | CA2172245C (en) |
DE (1) | DE69430823T2 (en) |
DK (1) | DK0759774T3 (en) |
ES (1) | ES2178656T3 (en) |
HK (1) | HK1014155A1 (en) |
NZ (1) | NZ275205A (en) |
PT (1) | PT759774E (en) |
WO (1) | WO1995008344A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
JPH09502987A (en) * | 1993-09-22 | 1997-03-25 | ゾーマ コーポレイション | Method of treating Gram-negative bacterial infections by administration of bactericidal / permeabilized (BPI) protein products and antibiotics |
US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
JP2001520631A (en) * | 1995-07-20 | 2001-10-30 | ゾーマ コーポレイション | Antifungal peptide |
AUPN771596A0 (en) * | 1996-01-25 | 1996-02-15 | Mclean, Allan Joseph | Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
PT914144E (en) * | 1996-05-10 | 2001-05-31 | Univ Texas | THERAPEUTIC UTILIZATIONS OF BIP PROTEIN PRODUCTS AGAINST HUMAN MENINGOCOCCEMIA |
WO1997044056A1 (en) * | 1996-05-23 | 1997-11-27 | Xoma Corporation | Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
US6482796B2 (en) | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US6406880B1 (en) | 1997-05-02 | 2002-06-18 | Integrated Research Technology, Llc | Betaines as adjuvants to susceptibility testing and antimicrobial therapy |
WO1998050576A1 (en) * | 1997-05-02 | 1998-11-12 | Integrated Research Technology, Llc | Betaines as adjuvants to susceptibility testing and antimicrobial therapy |
US7067500B2 (en) * | 1997-05-02 | 2006-06-27 | Integrated Research Technology, Llc | Betaines as adjuvants to susceptibility testing and antimicrobial therapy |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
WO1999052357A1 (en) * | 1998-04-14 | 1999-10-21 | Ribogene, Inc. | Assays for inhibitors of bacterial translation initiation factor 3 |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US5977091A (en) * | 1998-09-21 | 1999-11-02 | The Research Foundation Of State University Of New York | Method of preventing acute lung injury |
US6790661B1 (en) * | 1999-07-16 | 2004-09-14 | Verax Biomedical, Inc. | System for detecting bacteria in blood, blood products, and fluids of tissues |
US6696239B1 (en) * | 2000-04-20 | 2004-02-24 | Biolog, Inc. | Comparative phenotype analysis for assessment of biological active compounds such as antimicrobials |
US20020173464A1 (en) * | 2000-12-01 | 2002-11-21 | King George L. | Modulation of pericyte proliferation |
WO2002060879A2 (en) | 2000-12-15 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | Bacterial gyrase inhibitors and uses thereof |
US6835536B2 (en) | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
AU2002328203C1 (en) | 2001-08-24 | 2009-01-08 | Migenix Inc. | Antimicrobial and anti-inflammatory peptides |
US20030232401A1 (en) * | 2002-06-12 | 2003-12-18 | Pugia Michael J. | Bacterial test method by glycated label binding |
US20040037895A1 (en) * | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
MXPA05007743A (en) * | 2003-01-21 | 2005-11-04 | Ecopia Biosciences Inc | Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals. |
US7655646B2 (en) * | 2003-01-21 | 2010-02-02 | Thallion Pharmaceuticals, Inc. | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals |
WO2005024025A1 (en) * | 2003-09-11 | 2005-03-17 | Ecopia Biosciences Inc. | Polyene polyketides and methods of production |
US20060106028A1 (en) * | 2004-11-08 | 2006-05-18 | Ecopia Biosciences, Inc. | Polycyclic aromatics and derivatives thereof and processes for their preparation |
EP1741440A1 (en) * | 2005-07-08 | 2007-01-10 | Mellitus S.L. | Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders |
US20080114054A1 (en) * | 2006-11-14 | 2008-05-15 | Rath Microbes | Compositions and methods for reducing antimicrobial resistance of microbes |
US8871929B2 (en) | 2010-08-03 | 2014-10-28 | Merck Sharp & Dohme Corp. | Fused-imidazoyl compounds useful as antimicrobial agents |
CN103443096B (en) | 2011-01-14 | 2016-06-29 | 沃泰克斯药物股份有限公司 | Gyrase and topoisomerase I V inhibitor |
WO2012112438A2 (en) * | 2011-02-16 | 2012-08-23 | The Penn State Research Foundation | Anti-microbial agents and compositions and methods of production and use thereof |
EP2721026B1 (en) | 2011-06-20 | 2016-03-02 | Vertex Pharmaceuticals Incorporated | Phosphate esters of gyrase and topoisomerase inhibitors |
US9018216B2 (en) | 2012-07-18 | 2015-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
WO2014026143A1 (en) * | 2012-08-09 | 2014-02-13 | Pono Corporation | Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof |
WO2014160814A1 (en) * | 2013-03-26 | 2014-10-02 | Rutgers, The State University Of New Jersey | Synthetic and enhanced bacterial killing involving bicyclomycin |
JP2018529689A (en) * | 2015-09-17 | 2018-10-11 | ソウル大学校産学協力団Seoul National University R&Db Foundation | Cleaved or folded helical peptides or peptide analogs showing antibacterial activity against gram-negative bacteria and uses thereof |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
US20210023101A1 (en) * | 2017-07-19 | 2021-01-28 | The University Of North Carolina At Chapel Hill | Potentiation of antibiotic effect |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5028251A (en) * | 1973-07-12 | 1975-03-22 | ||
JPS55134471A (en) * | 1979-04-04 | 1980-10-20 | Toshiba Corp | Sales management system in small-scale computer constitution |
CA1237671A (en) * | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
JPS60128596A (en) * | 1983-12-15 | 1985-07-09 | 東芝テック株式会社 | Electronic cash register |
JPS619790A (en) * | 1984-06-25 | 1986-01-17 | オムロン株式会社 | Electronic cash register |
US4863727A (en) * | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
EP1659132A1 (en) * | 1987-08-11 | 2006-05-24 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
AU3772289A (en) * | 1988-06-23 | 1990-01-12 | Associates Of Cape Cod, Inc. | Endotoxin binding protein and uses thereof |
US5334584A (en) * | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
EP0563222B1 (en) * | 1990-12-03 | 1998-02-25 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5156665A (en) * | 1991-01-03 | 1992-10-20 | Rohm And Haas Company | Antimicrobial compositions comprising iodopropargyl compounds and isothiazolones and methods of controlling microbes |
EP0605653A4 (en) * | 1991-09-26 | 1995-03-15 | Incyte Pharma Inc | A new form of liposaccharide binding protein (lbp). |
ES2132239T3 (en) * | 1992-05-19 | 1999-08-16 | Xoma Corp | IMPROVED METHODS FOR THE PREPARATION OF BINDING PROTEINS TO ENDOTOXINS. |
US5643570A (en) * | 1992-05-19 | 1997-07-01 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
WO1994017819A1 (en) * | 1993-02-02 | 1994-08-18 | Xoma Corporation | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
DE69410254T2 (en) * | 1993-03-12 | 1998-12-17 | Xoma Corp | TREATMENT OF MYCOBACTERIAL DISEASES THROUGH THE ADMINISTRATION OF BACRERIAL-KILLING, PLEASURE-INCREASING PROTEIN FRAGMENTS |
DK0690872T3 (en) * | 1993-03-12 | 1999-05-10 | Xoma Corp | Biologically active peptides from bacterial / permeability enhancing protein functional domains and uses thereof |
US5348942A (en) * | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
EP1129718A3 (en) * | 1993-03-12 | 2002-05-22 | XOMA Technology Ltd. | Therapeutic uses of bactericidal/permeability increasing protein products |
JPH09502987A (en) * | 1993-09-22 | 1997-03-25 | ゾーマ コーポレイション | Method of treating Gram-negative bacterial infections by administration of bactericidal / permeabilized (BPI) protein products and antibiotics |
-
1994
- 1994-09-22 JP JP7509977A patent/JPH09502987A/en not_active Expired - Lifetime
- 1994-09-22 WO PCT/US1994/011225 patent/WO1995008344A1/en active IP Right Grant
- 1994-09-22 AU AU80740/94A patent/AU695814B2/en not_active Ceased
- 1994-09-22 CA CA002172245A patent/CA2172245C/en not_active Expired - Fee Related
- 1994-09-22 ES ES94931793T patent/ES2178656T3/en not_active Expired - Lifetime
- 1994-09-22 US US08/311,611 patent/US5523288A/en not_active Expired - Lifetime
- 1994-09-22 DE DE69430823T patent/DE69430823T2/en not_active Expired - Fee Related
- 1994-09-22 DK DK94931793T patent/DK0759774T3/en active
- 1994-09-22 NZ NZ275205A patent/NZ275205A/en not_active IP Right Cessation
- 1994-09-22 PT PT94931793T patent/PT759774E/en unknown
- 1994-09-22 EP EP94931793A patent/EP0759774B1/en not_active Expired - Lifetime
- 1994-09-22 AT AT94931793T patent/ATE218880T1/en not_active IP Right Cessation
-
1996
- 1996-06-03 US US08/657,162 patent/US6140306A/en not_active Expired - Fee Related
-
1998
- 1998-12-24 HK HK98115454A patent/HK1014155A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0759774A1 (en) | 1997-03-05 |
PT759774E (en) | 2002-11-29 |
HK1014155A1 (en) | 1999-09-24 |
AU695814B2 (en) | 1998-08-20 |
NZ275205A (en) | 1998-03-25 |
US6140306A (en) | 2000-10-31 |
ES2178656T3 (en) | 2003-01-01 |
JPH09502987A (en) | 1997-03-25 |
AU8074094A (en) | 1995-04-10 |
CA2172245C (en) | 2003-04-08 |
EP0759774B1 (en) | 2002-06-12 |
US5523288A (en) | 1996-06-04 |
ATE218880T1 (en) | 2002-06-15 |
DE69430823T2 (en) | 2003-02-20 |
WO1995008344A1 (en) | 1995-03-30 |
DK0759774T3 (en) | 2002-10-07 |
DE69430823D1 (en) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2172245A1 (en) | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein | |
ATE219684T1 (en) | ANTI-GRAM POSITIVE BACTERIAL METHODS AND AGENT | |
GEP19991538B (en) | Derivatives of Erytromycin and Pharmaceutical Composition on their Basis | |
EP1283050A3 (en) | Improved therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products | |
PT806941E (en) | LIPOSOMIC ANTI-BACTERIAL COMPOSITIONS OF LOW RIGIDITY | |
RU93004457A (en) | 1-CARBES- (1-DETIA) -CEFITS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION | |
CA2058592A1 (en) | Antibacterial agents | |
CA2351429A1 (en) | 13-membered azalides and their use as antibiotic agents | |
CA2254682A1 (en) | Method of treating eye infections with azithromycin | |
EP1019084A4 (en) | Novel antimicrobial polypeptide and methods of use | |
DE60027472T2 (en) | METHOD AND COMPOSITION FOR TREATMENT AND / OR PROPHYLAXIS OF ANTIBIOTICUM RESISTANT MICROORGANISM INFECTIONS | |
AU7792294A (en) | Antibacterial composition containing multimeric alpha-lactalbumin | |
HUP0401586A2 (en) | Antibacterial agent | |
CA2468036A1 (en) | A method of treating bacterial infections using gemifloxacin or a salt thereof and a .beta.-lactam antibiotic | |
Calandra | Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. | |
ZA947394B (en) | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic | |
Kern et al. | In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives | |
Bartoloni et al. | The influence of ofloxacin versus trimethoprim-sulfamethoxazole on the aerobic flora in granulocytopenic subjects | |
Liubchenko et al. | Experimental technological model for the combination of antibacterial drugs that provide anti-microbial effects for treatment of staphylococcal infections | |
Bustamante | Initial empiric therapy for fever in neutropenia | |
Van Der Waaij et al. | Infection prevention in neutropenic patients | |
IT1313628B1 (en) | Use of gemifloxacin compounds, which can be active against bacterial strains resistant to other antibiotics, in treatment of infections caused by respiratory tract pathogenic bacteria | |
RU93047438A (en) | METHOD OF TREATMENT OF PUSH-INFLAMMATORY PROCESSES | |
ES2076107A1 (en) | Macrolid antibiotic derivatives having rings with 16 members |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |